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Abstract: This study examined the effects of endo-
genous urokinase (uPA) on lipopolysaccharide
(LPS)-stimulated tumor necrosis factor a (TNF-a)
secretion in THP-1 mononuclear phagocytes. Anti-
uPA monoclonal antibody (mAb) suppressed LPS-
driven TNF-czsecretion by 61.6 ± 5.9% (P < .001),
and PAl-i, a uPA inhibitor, suppressed it to 53.1 ±
8.2% ofthe control value (P < .001). Up-regulation
of TNF-cx mRNA was suppressed in parallel with
secreted TNF-cz protein. TNF-a secretion was unaf-
fected by depleting plasminogen or by aprotinin, a
plasmin inhibitor. When endogenous uPA was dis-
placed from the cell, exogenous high-molecular-
weight (intact) uPA augmented LPS-driven TNF-cc
secretion. By contrast, a uPA fragment containing
the catalytic domain was inhibitory, and the uPA
receptor-binding domain had no effect. We conclude
that endogenous uPA amplifies TNF-a neosynthesis
of LPS-stimulated THP-1 mononuclear phagocytes.
The effect requires intact uPA and is independent of
plasmin activity. This represents a novel mechanism
by which a mononuclear phagocyte-derived protease
contributes to generating proinflammatory signals. J.
Leukoc. Rio!. 59: 302-311; 1996.
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INTRODUCTION
Proteases are integral to inflammatory responses, not only
by contributing to tissue injury and remodeling but also by
regulating the activation and function of inflammatory
cells. Mononuclear phagocytes (Ms) use the plasminogen
activator system as an important mechanism for regulating
the environment in the inflammatory milieu [1, 2]. These
cells synthesize and secrete urokinase-type plasminogen
activator (uPA) and PA inhibitors (principally PAI-2) and
express specific high-affinity uPA receptors on the plasma
membrane (uPAR; CD87) [1, 2]. Cytokines stimulate neo-
synthesis of all elements of the PA-plasmin system, and in
some cases there is significant cytokine specificity [1, 3,
4]. The role of the uPA-plasmin system in M function has
been only partially elucidated, but it appears to be particu-
larly important for tissue invasion, chemotaxis, and remod-
eling extracellular matrix proteins [2, 5-8]. Beyond the
effect of these enzymes on stromal integrity, evidence is
accumulating that uPA and plasmin are involved in regu-
lating the release of cytokines or activation of cytokines
from latent forms [9-11]. In addition, uPA can regulate
leukocyte differentiation and activation by mechanisms
quite distinct from those of its catalytic functions. In neu-
trophils, binding uPA to plasma membrane uPAR triggers
signal transduction to the cell interior, as evidenced by
calcium fluxes and protein tyrosine phosphorylation [12,
13]. Engagement of uPAR by uPA enhances uPAR-medi-
ated adhesion to vitronectin and differentiation of M-like
cells [14, 15]. In some instances, the amino terminus of
uPA (bearing the uPAR binding domain) is sufficient to
trigger a response, and uPA enzymatic activity, located in
the carboxyl terminus, is entirely unnecessary [13, 15]. In
neutrophils, both the amino and carboxyl terminal regions
of uPA must interact with partner proteins to initiate signal
transduction [12]. Thus, distinct elements of the uPA
structure can subserve diverse mechanisms for modulating
leukocyte function.
One of the difficulties inherent in studying the uPA-
plasmin system in cell culture is that M4s produce suffi-
cient PA inhibitors to complicate experimental
manipulation of uPA function [2]. One means of circum-
venting this problem is to study the THP-1 human mono-
cytic leukemia line. THP-1 cells, which have been used
extensively as models of Ms, express uPA and uPAR
normally but produce an inactive form of PAI-2 [16, 17].
As a result, functional PA activity is readily measured in
cell supernatants. In this study, we sought to determine
whether the PA-plasmin system affects tumor necrosis fac-
tor cx (TNF-a) secretion by Ms, using THP-1 cells as a
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model system. Ms express a cell-associated pool of TNF-
a, and there is some evidence that optimal secretion of
TNF-a requires the action of an unspecified serine pro-
tease(s) [18, 19]. Along with its effects on other cytokines,
modulating expression of TNF-a would be a powerful way
for the uPA-plasmin system to influence inflammatory re-
actions [20]. We demonstrate that endogenously generated
uPA modulates stimulation of TNF-a neosynthesis in re-
sponse to bacterial lipopolysaccharide (LPS). We further
show that the intact structure of high-molecular-weight
uPA is necessary for this function, and the effect is inde-
pendent of plasminogen activation.
MATERIALS AND METHODS
Reagents
Human plasminogen (PLC) was purified from human plasma by lysine-
Sepharose chromatography [21]. The eluate migrated at 90 kd on so-
dium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and
hydrolyzed the plasmin substrate thiobenzyl benzyloxycarbonyl-L-lysi-
nate (Z-LTBE; Calbiochem) after activation with high-molecular-weight
(HMW) uPA (American Diagnostica, Greenwich, CT) [22]. Similarly,
fetal bovine serum (FBS; Hyclone, Logan, UT) was depleted of plasmi-
nogen by two consecutive passages over lysine-Sepharose. To confirm
that the depletion step was effective, an aliquot of FBS was briefly
acidified to inactivate antiplasmins [23], followed by treatment with
uPA (10 milliPloug units (mPU)/ml). The sample was then assayed for
plasmin activity, using the Z-LTBE substrate. Even after markedly pro-
longed incubation (>4 h) with uPA and then with Z-LTBE, there was
no evidence of plasmin generation from the depleted serum, while plas-
mm activity was evident in parallel assays of FBS that was briefly
acidified but not passed over lysine-Sepharose. Western blots of normal
and lysine-Sepharose--adsorbed FBS were also performed, using a goat
anti-bovine PLC primary antibody (American Diagnostica).
Neutralizing murine monoclonal antibody (mAb) to human uPA (im-
munoglobulin Cl; catalog number 394) was obtained from American
Diagnostica. According to the manufacturer’s specifications, this mAb
recognizes one- and two-chain forms of uPA and uPAR-bound uPA. An
isotype-matched mAb (anti-tissue factor, catalog number 4503) and
aprotinin were also obtained from American Diagnostica. The murine
anti-human uPAR mAb (clone 3B10, IgG2a), also designated anti-Mo3f,
was prepared as previously described and recognizes an epitope in the
ligand binding region (domain 1) [24, 25]. Recombinant human PAl-i
was generously provided by David Ginsburg, M.D., Howard Hughes
Medical Institute, University of Michigan Medical Center. Mixing stud-
ies against HMW-uPA confirmed that the PAl-i (25 ng/ml, as was used
in the present studies) inhibited 350 mPU uPA/mI and retained 100
mPU/ml inhibitory activity even after incubation at 37#{176}Cfor 2 h. Re-
combinant human uPA amino terminal fragment (uPA-ATF) containing
the uPAR-binding region (amino acids 1-135), but not the active site,
was generously provided by Richard H. Simon, M.D., University of
Michigan. uPA-ATF was produced with the Xpress protein expression
system in Escherichia coli (Invitrogen, San Diego, CA). The uPA-ATF is
synthesized from the pTrcHis vector as a fusion protein with six histid-
me residues at the NH2 terminus. The fusion protein is then purified by
ProBond metal affinity chromatography (Invitrogen), and the recombi-
nant uPA-ATF (18.7 kd) is removed from the NH2-terminal fusion
peptide at an enterokinase cleavage site. Bacterial lipopolysaccharide
from E. coli 0111:B4 was purchased from Sigma Chemical Co., St. Louis
MO. The human TNF-cx eDNA (0.8 kb) was obtained from the American
Type Culture Collection, Rockville, MD.
The THP-1 monocytic leukemia cell line was obtained from t1e Ameri-
can Type Culture Collection. Cells were propagated in 75-cm polysty-
rene flasks (Costar, Cambridge, MA) in standard medium consisting of
RPM! 1640 (Gibco, Grand Island, NY) supplemented with penicillin
(100 U/mI), streptomycin (100 .tg/ml), gentamicin (100 tg/ml), glu-
tamine (2 mM), and 10% FBS. To ensure that experiments were per-
formed on cells in a uniform growth phase, cells were always passed into
fresh medium (10 cells in 50 ml) 24 h prior to LPS stimulation. After
washing, cells were dispensed into 96-well round-bottom plates (106
cells in a final volume of 200 p1), with additives as indicated. Cells were
cultured for 24 h at 37#{176}Cin humidified air supplemented with 5% CO2.
Conditioned medium was then removed and cleared of cells by centrifu-
gation. After washing in fresh medium, cell lysates were prepared by
sonication (5 x 106 cells/ml medium).
Immunoassays
TNF-a was quantitated with an enzyme immunoassay kit purchased
from Cistron Co., Pinebrook, NJ. This assay employs a monoclonal
capture Ab and a detection system consisting of a rabbit anti-human
TNF-a Ab and a peroxidase-conjugated goat anti-rabbit Ab. The en-
zyme immunoassay for interleukin-8 (IL-8) was prepared as described
previously, using a rabbit anti-human IL-B as both capture and detec-
tion antibodies, the latter being biotinylated and measured with a per-
oxidase-streptavidin conjugate [26].
lmmunofluorescence flow cytometry
To measure plasma membrane uPAR, cells were suspended in staining
buffer (phosphate-buffered saline with 1% bovine serum albumin and
0.1% sodium azide, pH 7.4), incubated with the murine anti-human
uPAR antibody (3B10) for 30 mm, 4#{176}C,and Libeled for 30 mm, 4#{176}C,
with R-phycoerythrin-conjugated goat anti-mouse F(ab’)2 fragment
(Jackson Immunological Research, West Grove, PA). For negative con-
trols, cells were always stained in parallel with the secondary antibody
alone and with an irrelevant isotype-matched (lgG2a) primary antibody.
Alternatively, cells were directly labeled with fluorescein isothiocyanate
(FITC)-conjugated anti-uPAR mAb (3B10), using FITC-IgG to measure
nonspecific staining. Intact (live) cells were selected by gating (log
forward angle versus log right angle light scatter). Immunofluorescence
intensity was assessed as a measure of relative antigen expression, using
an EPICS C flow cytometer (Coulter Electronics, Hialeah, FL) with a
logarithmic amplifier. The channel number (log scale) representing the
mean fluorescence intensity (major fluorescence peak) was determined
from approximately 5000 cells. The corresponding linear fluorescence
intensity channel was then calculated from a logarithmic-linear calibra-
tion formula. Specific fluorescence intensity was calculated by subtract-
ing the values of the negative controls, using the linear scale.
mRNA analysis
For these exgeriments. THP-i cells were cultured in serum-containing
medium (10 cells/ml) in 75-cm2 flasks in the presence or absence of
LPS (0.5 ig/ml) and anti-uPA mAb (1.6 ig/ml) or PAl-i (5 ng/ml) for
2 and 3 h. Cells were washed with RPMI 1640, and total cellular RNA
was extracted using the Ultraspec RNA isolation system (Biotecx Labo-
ratories, Houston, TX). The RNA was quantitated by spectroscopy at
260 nm and size fractionated electrophoretically on 1% agarose gels
containing 3.5 pM formaldehyde and 20 pg/ml ethidium bromide, as
described previously [27]. The RNA was transferred to Hybond nylon
filters (Arnersham, Arlington Heights, IL) and fixed by exposure to
ultraviolet (UV) light. Ribosomal bands on the filters were visualized
under UV light, providing internal size markers for each lane and also
confirming that the RNA was loaded and transferred equall among
corresponding lanes. The TNF-a eDNA was labeled with [y- 2P]ATP
(Amersham) by random priming [28]. The nylon filters were then hy-
bridized with 106 cpm of [32P]cDNA for 18 h at 65#{176}C,followed by serial
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mm, then 0.2x SSC, 0.1% SDS at 68#{176}Cfor 20 mm. The filters were then
developed by autoradiography, using Hyperfilm (Amersham) at -70#{176}C.
Statistics
The results are drawn from a data pool ranging from 5 to 15 experiments,
as indicated. Comparisons between group means were performed using
an unpaired, two-tailed Student’s t-test [29]. Where appropriate, a
paired f-test was used. Bonferroni’s correction was utilized (as mdi-
cated) when multiple comparisons with a single control were made.
Statistical significance was taken to represent a P value  .05.
RESULTS
Effects of anti-uPA mAb on TNF-a secretion
THP-1 cells were cultured under control conditions (me-
dium alone) or stimulated with LPS, either 0.5 or 5.0
jig/mi. Anti-uPA mAb was added to the cultures simulta-
neously with the addition of LPS. Each batch of mAb used
during the course of these experiments was screened to
determine the concentration that had the optimal effect on
TNF-a production. There was significant variability be-
tween the batches, so the final concentration of mAb used
in these experiments ranged from 1.6 to 10 .tg/ml. Cell
viability was routinely >95% at the onset of stimulation
and >90% after 24 h. Neither the LPS nor the anti-uPA
mAb adversely affected cell viability.
When cultured in medium alone, THP-1 cells secreted
a minimal amount of TNF-a (< 0.1 ng/ml; Fig. 1). Pre-
liminary experiments indicated that the maximal increase
in TNF-a secretion reached a plateau with LPS  1 ig/ml.
Therefore, these experiments were performed with LPS
concentrations of 5.0 and 0.5 .tg/ml, which allowed us to
examine both maximal and submaximal stimulation by
LPS. As shown in Figure 1, LPS increased TNF-a secre-
I61.6 ± 5.9 % INHIBITION 
Fig. 1. Effects of anti-uPA mAb on LPS-induced secretion of TNF-a.
Unstimulated THP-1 M4s and cells incubated with anti-uPA mAb alone
expressed < 0.1 ng/ml TNF-a during a 24-h incubation. LPS at 0.5 j.tg/ml
and 5.0 tg/ml induced >30-fold increases in TNF-a secretion. Anti-uPA
mAb added coincidentally with LPS significantly reduced TNF-a secre-
tion. Bars indicate the mean ± SE%1, n 15. The inset values indicate the
mean ± SEM of the percent inhibition. * < 
tion more than 30-fold above the level produced by Un-
stimulated cells. Anti-uPA mAb alone had no effect on
TNF-cz secretion, but it significantly reduced the amount
of TNF-a secretion induced by either concentration of LPS
(Fig. 1). Mean TNF-a secretion was reduced from 3.2 to
1.34 ng/ml with 0.5 j.tg/ml LPS (P < .001) and from 3.67
to 1.53 ng/ml with 5.0 jig/ml LPS (P < .001). Comparing
the effect of the antibody to the LPS control for each ex-
periment, these values represented 57.8 ± 6.6% and 61.6
± 5.9% reductions in TNF-a secretion, respectively (both
P < .001). Preliminary experiments also confirmed that
adding these concentrations of anti-uPA mAb directly to
samples containing TNF-a standard had no effect on
measurement of TNF-a in the enzyme immunoassay (not
shown). In addition, the isotype-matched control (anti-tis-
sue factor) mAb (10 tWml) had no effect at all on LPS (0.5
j.tg/ml)-induced TNF-cz secretion (98.2 ± 2.4% of LPS con-
trol, n = 5) and had no direct effect on the TNF-a assay.
TNF-a is processed and secreted efficiently, so most
TNF-cz is found in the conditioned medium, with a very
minor fraction remaining cell associated [20]. Thus, the
possibility was considered that the anti-uPA mAb was in-
terfering with processing and secretion of TNF-a. There-
fore, the cell-associated pool was assayed to determine
whether the reduction in the secreted fraction was accom-
panied by a reciprocal accumulation within the cells. The
amount of TNF-cz measured in cell lysates was unaffected,
as anti-uPA mAb treatment and PA!-! (see below) left LPS
(0.5 ig/ml)-stimulated cells with 90.5% and 93.5%, re-
spectively, of the cell-associated TNF-a levels found in
LPS-treated controls (P > .5). TNF-a on the plasma mem-
brane (quantitated by flow cytometry) was likewise unaf-
fected by inhibition of uPA (not shown).
Effects of plasminogen depletion and plasmin
inhibition
Because the anti-uPA mAb used in the experiments de-
scribed above neutralizes the catalytic activity of uPA, we
hypothesized that TNF-a secretion was facilitated by plas-
mm, the product of uPA-mediated activation of ambient
PLG. To address this question, these experiments were
repeated using PLG-depleted FBS. To exclude the possi-
bility that lysine-Sepharose adsorption had spurious, unan-
ticipated effects on the ability of FBS to support THP-1
activation, PLG-depleted FBS was also reconstituted with
0.25 ptM human PLG. PLG depletion had no effect on the
ability of the anti-uPA mAb to suppress LPS-induced TNF-
a secretion (Fig. 2A), as the results effectively duplicated
those shown in Figure 1. Likewise, the addition of exoge-
nous human PLG has no effect, as suppression by the
anti-uPA mAb matched the effects seen with normal and
PLG-depleted FBS (Fig. 2B). In addition, these experi-
ments were performed in serum-free medium (MAC-SFM;
Gibco). LPS induced only a weak increase in TNF-a se-
cretion in this medium, but anti-uPA mAb suppressed
TNF-cx secretion as it did in the presence of serum (not
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Fig. 2. Inhibitory effect ofanti-uPA mAb on LPS-induced TNF-a secretion is independent ofplasminogen activation. (A) Depleting fetal bovine serum
ofplasminogen (PLC) did not alter the inhibitoty effect ofanti-uPA mAb on LPS-induced TNF-a secretion. Data are expressed as in Figure 1, n 6.
*P < .001. (B) Reconstituting PLG-depleted fetal bovine serum with 0.25 .tM human PLG did not alter the suppressive effects of anti-uPA mAb on
LPS-induced TNF-a secretion. Data are expressed as in Figure 1, n 6. *P < .001. (Inset: Western blot of normal and PLC-depleted FBS, using a
goat anti-bovine PLC antibody. Normal FBS has immunoreactive PLC, which is completely removed by lysine-Sepharose adsorption.)
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into the cultures bound to THP-1 plasma membranes, the
cells were incubated in 15 mM tranexamic acid for 5 mm
at 25#{176}C,followed by washes in PBS, to displace PLG from
the cell surface [30]. When these cells were cultured in
PLG-depleted serum, anti-uPA mAb still suppressed LPS-
induced TNF-a secretion, just as in Figure 2A (not
shown).
These data suggested that uPA can modulate TNF-a
secretion even in the presence of minimal PLG. In further
support of this conclusion, we examined the effect of aprot-
mm at a concentration (10 ig/ml) that effectively inhibits
plasmin activity but does not affect uPA activity [31J.
Aprotinin had no effect on LPS-stimulated TNF-a secre-
tion (Fig. 3). For comparison, cells were treated with re-
combinant PAl-i, which is a highly specific PA inhibitor
with virtually no antiplasmin activity. As noted in Materi-
als and Methods, the PAl-i (25 ng/ml) inhibited 350
mPU/ml HMW-uPA in an in vitro esterolytic assay,
whereas we have previously found only 42 ± 3 mPU/1O6
cells plasma membrane-associated uPA activity on THP-1
cells [17]. Because PAl-i retains its activity under tissue
culture conditions for only a brief period of time [32], it
was added repeatedly (5 ng/well) at hours -1, 0, 1, and 3,
relative to the addition of LPS. As shown in Figure 3,
PAl-i substantially reduced TNF-a secretion, to 53.1 ±
8.2% of control (P < .001), effectively reproducing the
effects of the anti-uPA mAb. When added without LPS,
neither aprotinin nor PAl-i induced any increase in TNF-
a relative to unstimulated cells (it was also verified that
adding PAl-i at the first time point was unnecessary and
adding aprotinin 1 h before LPS produced the same results
as adding the two simultaneously).
TNF-a secretion was consistently suppressed by the
other uPA inhibitors tested, including recombinant PAI-2,
which effectively duplicated the results obtained with PA!-
1 (not shown). In addition, amiloride, a potent uPA inhibi-
tor [33], blocks TNF-a secretion quite effectively, but it
was not used in this study because it also blocks IL-8
expression [34], unlike the effects of anti-uPA mAb (see
below), suggesting other, unrelated mechanisms of action.
Mechanism of anti-uPA mAb-mediated
suppression of TNF-a secretion
To determine how anti-uPA mAb suppressed LPS-medi-
ated TNF-cz secretion, we first examined whether uPA af-
fects all LPS-mediated signaling. We therefore examined
the effects of anti-uPA mAb on secretion of another LPS-
responsive cytokine, IL-8. Anti-uPA mAb had no suppres-
sive effect at all on interleukin-8 secretion (Fig. 4). In
fact, anti-uPA mAb increased 1L-8 secretion to 126.4 ±
12.3% of the LPS control, approaching statistical signifi-
cance (P = .08). This would suggest that uPA participates
in a signaling mechanism that selectively links LPS stimu-
lation to amplified TNF-a expression, rather than a com-
mon pathway for all LPS-mediated cell activation.
To determine the time period over which the anti-uPA
mAb is effective, THP-1 cells were stimulated with LPS as
described above, and anti-uPA mAb was added either co-
incidentally with LPS (time 0) or after an interval of 1, 2,
3, or 4 h. The cells were left to incubate for a total of 24 h,
and the conditioned medium was harvested. As shown in
Figure 5, the inhibitory effect of anti-uPA mAb dimin-
ished very rapidly, as delaying the addition of mAb for
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Fig. 3. Aprotinin, a selective plasmin inhibitor at 10 tg/ml, has no effect
on TNF-a secretion induced by 0.5 tWml LPS, whereas recombinant
PAl-i (added as described in Results) significantly suppresses TNF-a
secretion. The values indicate the TNF-a secretion as percentages of the
LPS control, mean ± SEM, n 10. J3 < .001.
even 1 h led to a statistically insignificant effect on TNF-a
secretion. This finding is most consistent with an effect on
activation signaling, rather than an effect on newly synthe-
sized TNF-a.
Analysis of TNF-cz mRNA levels was performed to de-
lineate more precisely the stage in LPS-induced TNF-a
expression that is modulated by uPA. Representative
Northern blots are shown in Figure 6. Preliminary experi-
ments established that the LPS-induced increase in TNF-a
mRNA levels was evident at 1 h, with a peak at 2-3 h, and
substantially waned by 4-S h (not shown). Coincubating
THP-1 cells with the anti-uPA mAb or PAl-i substantially
reduced the LPS-driven up-regulation of TNF-a mRNA,
most prominently at the 3-h time point. To demonstrate the
reproducibility of these results, densitometry measure-
ments were performed on three separate Northern blots,
comparing LPS versus LPS + anti-uPA mAb at the 3-h
time point (one of these experiments is shown in Fig. 6). In
these three experiments, coincubation with anti-uPA mAb
reduced the density of the TNF-a mRNA band by 55±6%
(P < .02). These findings show that uPA is involved in
regulating TNF-a neosynthesis rather than terminal proc-
essing of preformed TNF-a precursor, conforming well
with the early time frame during which uPA exerts its
effects.
Binding PAl-i or the anti-uPA mAb to receptor-associ-
ated uPA on the plasma membrane may trigger internali-
zation of the receptor-ligand complex [35]. To determine
whether this is a potential mechanism for the effects of
these proteins on TNF-a secretion, cells were incubated
with the anti-uPA mAb or PAl-i for 20, 40, or 60 mm,
along with LPS (0.5 jig/mi), as described above. The level
of uPAR on the cell surface was then determined by immu-
nolabeling, using anti-uPAR mAb + phycoeiythrin-goat
anti-mouse Ig (PAl-i pretreatment) or direct labeling with
FITC-anti-uPAR mAb (anti-uPA mAb pretreatment).
uPAR was quantitated only within 1 h of stimulation, be-
cause anti-uPA mAb suppresses LPS-driven TNF-a secre-
tion only within this narrow time frame. As shown in
Figure 7, the anti-uPA mAb had no effect at all on uPAR
expression. The indirect staining method used for cells
treated with PAl-i yielded a weaker and more variable
signal, but still there was no effect on uPAR at 20 and 40
mm and there was a statistically insignificant downward
trend at 60 mm. Thus, it is unlikely that these interven-
tions affect TNF-a secretion by causing a net loss of uPA-
uPAR complexes from the plasma membrane.
Finally, experiments were performed to determine
whether specific elements of the uPA structure are respon-
sible for modulating TNF-a secretion. THP-1 cells were
washed for 5 mm with 50 mM glycine buffer, pH 3.0, to
displace endogenously generated uPA from plasma mem-
brane uPAR [1]. Cells were immediately resuspended in
culture medium with LPS (0.5 j.tg/ml), along with 1, 10, or
100 nM concentrations of HMW-uPA (intact), low-molecu-
lar-weight (LMW)-uPA (carboxyl terminal fragment bear-
ing the enzymatic active site but no uPAR-binding
domain), or uPA-ATF (amino terminal fragment bearing
the uPAR-binding domain but no active site). These con-
centrations were selected from preliminary data indicating
that a 100 nM concentration of uPA-ATF maximally dis-
placed endogenous uPA from cell surfaces. After culture
for 24 h, secreted TNF-cz was measured, as described pre-
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Fig. 4. Anti-uPA mAb does not inhibit IL-8 secretion induced by 0.5
ig/ml LPS. Unstimulated THP-1 M4s and cells incubated with anti-uPA
mAb alone expressed < 4 ng/ml IL-8, and LPS induced more than a
10-fold increase in IL-8 secretion during a 24-h incubation (P < .001).
Bars indicate the mean ± SEtI IL-8 levels in conditioned medium, n 6.
The addition of anti-uPA mAb to LPS treatment did not reduce TNF-a
secretion but rather increased secretion to 126.4 ± 12.3% of the LPS
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Fig. 5. Time course ofTNF-a inhibition by anti-uPA mAb. THP-1 cells
were stimulated with 0.5 iWinl LPS, anti-uPA mAb was added either
simultaneously (time 0) or after 1, 2, 3, or 4 h, and TNF-a secretion was
measured at 24 h. Anti-uPA significantly reduced TNF-a secretion only
at time 0. P < .05, using a paired f-test and Bonferroni’s correction; n
= 5. The triangle indicates LPS (0.5 )ig/ml) alone, mean ± srsi.
reduced and somewhat variable compared with previous
experiments. This certainly raises the possibility that the
acid treatment has nonspecific effects on THP-1 cell func-
tion, perhaps by displacing ligands from other surface re-
ceptors. Nonetheless, the addition of HMW-uPA
augmented the TNF-a output of LPS-stimulated cells in
five of five separate experiments (Fig. 8). By contrast,
LMW-uPA progressively consistently reduced TNF-a se-
cretion, even though the specific activities of the HMW-
uPA and LMW-uPA preparations are quite similar (1 j.tM
= 4400 IU/ml and 5280 IU/ml, respectively). Therefore,
the catalytic function of uPA alone is not sufficient to
enhance TNF-a secretion, consistent with the observed
independence of plasminogen activation. Suppression of
TNF-a secretion by LMW-uPA further suggests that this
uPA fragment may be competing with intact HMW-uPA
remaining on the cell surface after acid treatment. Alterna-
tively, LMW-uPA may be competing with HMW-uPA re-
leased from internal stores early during LPS stimulation.
Finally, uPA-ATF has no effect on TNF-cx secretion (n
4), indicating that uPAR occupancy alone cannot account
for the effects of uPA. Thus, the intact structure of HMW-
uPA is necessary for modulating TNF-a secretion. The
mechanism underlying the effect of HMW-uPA remains to
be elucidated, but HMW-uPA is known to participate in
activation signaling in neutrophils, a process that requires
intact uPA and coparticipation with uPAR and the adhe-
sion protein CR3 [12].
DISCUSSION
In this study, we have shown that uPA generated by the
THP-1 M4 line is necessary for maximal induction of TNF-
a neosynthesis by LPS. An mAb specific for the uPA ac-
tive site reduces TNF-cz secretion by approximately 60%,
and PAl-i, a highly specific PA inhibitor, has an identical
effect, suppressing TNF-cz secretion by approximately
50% (Figs. 1 and 3). Moreover, uPA appears to be directly
responsible for this effect, as plasmin formation is not re-
quired as an intermediate step. This is supported by dem-
onstrating that neither plasminogen depletion nor aprotinin
(a potent plasmin inhibitor) influences the suppressive ef-
fects of the anti-uPA mAb (Figs. 2 and 3). Moreover, ex-
ogenous uPA enhances TNF-ct secretion only if provided
in the high-molecular-weight form; the low-molecular-
weight form effectively blocks TNF-a secretion, despite its
preserved catalytic activity (Fig. 8). Collectively, these
findings indicate that a region of uPA very near the active
site is necessary for modulating TNF-a secretion, and al-
though uPA catalytic activity alone cannot account for this
effect, it may still prove to be one of several elements of
uPA function necessary for modulating TNF-a expression.
Future experiments using DFP-inactivated uPA and pep-
tide inhibitors of uPA should be very helpful in defining
the role of uPA activity, although the possibility will re-
main that the active site region of uPA serves other func-
tions, and modulating the active site may affect TNF-a
expression by mechanisms unrelated to blocking cleavage
of a uPA substrate. For this reason, defining the mecha-
nisms of action of uPA will be best achieved by fully
characterizing any partner proteins and substrates of uPA
cleavage during LPS stimulation. This information will also
assist in defining the role of uPAR binding. At present, the
data indicate that the uPAR-binding region of uPA is nec-
essary, but not sufficient, to regulate TNF-cx secretion.
Another novel conclusion of this study is that modulating
uPA function affects TNF-a neosynthesis at the mRNA
level (Fig. 6). The suppression of TNF-a mRNA up-regu-
lation by anti-uPA mAb and PAl-i is certainly sufficient to
explain the observed effects on TNF-a secretion. The
mechanism linking uPA to up-regulating TNF-a mRNA is
a key question, and some intriguing prospective mecha-
nisms must be considered. There is a growing appreciation
that uPA has noncatalytic functions relevant to M4 activa-
tion. In an M4-like cell line, uPA enhances uPAR-medi-
ated adhesion to vitronectin and also promotes phenotypic
differentiation [14, 15]. Binding uPA to uPAR initiates the
generation of intracellular signal transduction elements, as
evidenced by tyrosine phosphorylation of a 38-kd partner
protein in U937 cells [13] and by calcium fluxes generated
in neutrophils [12]. The impact of these events on
activation is poorly understood, as are the mechanisms by
which these responses are triggered. The urokinase recep-
tor is anchored to the plasma membrane by a glycosylphos-
photidylinositol linkage [36]. Like other surface proteins
lacking a transmembrane segment, uPAR (or uPA-uPAR
complexes) may utilize partner proteins to transmit activa-
tion signals. In neutrophils, CR3 (CD11b/CD18; Mac-i), a
leukadhesin of the 2 integrin family, is an obligate signal-
ing partner for uPA in triggering a calcium flux upon bind-
ing to uPAR [12]. Much akin to the present findings, only
intact uPA could initiate this response, and both carboxyl
and amino terminal fragments were ineffective. In this re-
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Fig. 6. Anti-uPA mAb and PAl-i suppress LPS-induced up-regulation ofTNF-a mRNA levels. Cells were cultured for 2 and 3 h in medium alone,
0.5 j.tg/ml LPS, LPS + anti-uPA inAb, and LPS + PAl-i (as indicated in Materials and Methods) and the Northern blots were probed with TNF-a
eDNA. TNF-a mRNA expression was up-regulated by LPS at 2 and 3 h. Coincubation with anti-uPA mAb or PAl-i substantially reduces the increase
in TNF-a mRNA. UV-illuminated ribosomal bands on the nylon filter are shown to confirm equal loading and transfer of RNA. Density measurements
of the Northern blots show that TNF-a mRNA levels of cells cotreated with anti-uPA mAb or PAL-i were reduced by 30% at 2 h and 60-65% at 3 h
relative to the LPS control at the appropriate time point.
gard, it is also noteworthy that CR3 has been shown to be
necessary for LPS-driven TNF-a secretion by THP-i cells
[16]. The possibility that formation of a uPA-uPAR-CR3
complex is a proximate means for regulating M activation
is under investigation. This putative mechanism is consis-
tent with the rapid, short-lived action of uPA but eventu-
ally must also satisfy the requirement for modulating
cytokine output in a selective fashion. The ability of uPA
to augment TNF-a secretion without affecting IL-8 secre-
tion will be useful in determining the mechanism of action,
because prior studies have shown that TNF-a and IL-8 are
generally regulated in tandem [37, 38].
In addition to the uPAR-mediated effects on adhesion
and activation signaling, the catalytic activities of both
uPA and plasmin can significantly affect other aspects of
M4 activation, as well as the composition of the inflamma-
tory milieu. Plasmin is a broad-spectrum endopeptidase
with a substrate range similar to that of trypsin, whereas
uPA has very few known substrates other than plasminogen
[2]. These include fibronectin, type IV gelatinase/col-
lagenase, hepatocyte growth factor/scatter factor
(HGF/SF), and uPAR itself [31, 39-41]. It is impossible at
present to implicate any of these specific uPA substrates
in modulating TNF-a expression. The 120-kd cell-binding
fragment of fibronectin can stimulate TNF-a secretion in
human monocytes, but uPA digestion is not known to yield
a fragment with this activity [41, 42]. At present, uPAR
cleavage products have no defined intrinsic biologic activi-
ties, other than vitronectin binding by domain 2/3 frag-
ments [15]. Ultimately, it will be necessary to characterize
Fig. 7. Cell surface expression of uPA receptor (uPAR) by LPS (0.5
tg/ml)-treated cells is not significantly affected by anti-uPA mAb or by
rPAI-1 (5 ng/ml) for 20, 40, or 60 mm. uPAR was measured by im-
munofluorescence flow cytometry, using direct labeling with FITC-anti-
uPAR mAb (anti-uPA mAb treatment) or indirect labeling (PAl-i
pretreatment). Specific fluorescence intensity (nonspecific staining sub-
tracted, linear scale) is expressed as a percentage of LPS-treated controls,
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Fig. 8. Effects of intact uPA and uPA fragments on LPS-driven TNF-a secretion by acid-washed THP-1 cells. Intact, high-molecular-weight uPA
(HMW-uPA) augments TNF-a secretion in a dose-related fashion, whereas low-molecular-weight uPA (LMW-uPA), bearing only the catalytic domain,
has a dose-related suppressive effect. The uPA amino terminal fragment (uPA-ATF) bearing only the receptor-binding domain does not affect TNF-a
secretion. The results offive (HMW-uPA and LMW-uPA) and four (uPA-ATF) separate experiments are shown. Each set ofsymbols represents the data
obtained from a single experiment, assayed in duplicate.
the range of substrates cleaved by uPA during LPS stimu-
lation to discriminate fully between the catalytic and non-
catalytic  mechanisms by which uPA affects activation
signaling.
The uPA regulation of TNF-a synthesis is one of many
examples of proteases modulating the function and secre-
tory output of M4s. Collectively, these proteases, many of
which are traditionally viewed as elements of the coagula-
tion and fibrinolytic pathways, act at all phases of M4
activation. Some, such as thrombin and factor Xa, act as
costimuli in inducing IL-i expression [43]. The mecha-
nisms underlying these effects are not well understood, but
M4s express receptors for both thrombin and factor X, and
some activation signals have been shown to require pro-
teolytic action, whereas others require only receptor bind-
ing without any requirement for enzymatic action [43-45].
In other instances, uPA and plasmin activities exert post-
synthetic regulation of the expression and function of cy-
tokines and growth factors. Endogenous uPA activity is
necessary for release of IL-i from its membrane-bound
form, but, unlike the present findings, active plasmin was
actually responsible for facilitating IL-i secretion [1 i].
Plasmin also converts latent transforming growth factor 
precursor to its active form, and uPA directly activates
HGF/SF precursor [9, iO]. Finally, plasmin can enhance
the bioactivity of basic fibroblast growth factor by releasing
it from extracellular matrix proteins [46]. Our demonstra-
tion that uPA affects initial up-regulation of TNF-cx neo-
synthesis is quite distinct from established effects of the
uPA-plasmin system on terminal processing of nascent cy-
tokines. Unspecified serine proteases susceptible to p-tolu-
ene-sulfonyl-L-arginine methyl ester have been implicated
in releasing the membrane-bound 26-kd form of TNF-a
from M plasma membranes to yield a mature i7-kd prod-
uct in conditioned medium [18, 19]. More recent evidence
indicates that this conversion from 26-kd to i7-kd forms is
also regulated by a unique metalloproteinase [20, 47].
These mechanisms of action cannot be reconciled with the
findings of the present study, suggesting that multiple pro-
teases regulate sequential steps in TNF-a synthesis and
secretion.
The results of this in vitro study suggest several poten-
tially important mechanisms by which uPA may regulate
inflammation in vivo. Local fluctuations in the expression
of uPA activity have been implicated in the pathogenesis
of inflammatory injury in vivo [2, 8, 48-Si]. The influx of
plasma-borne PA inhibitors is responsible for the defective
local fibrinolytic activity observed in severely inflamed
lung tissue [48, 49]. Similarly, sequential expression of PA
activity and PA inhibitors has been described in cutaneous
granulomas [50]. Because uPA gene expression is itself
responsive to many cytokines, including TNF-a, these ob-
servations complete a potential pathway of reciprocal acti-
vation that amplifies expression of both cytokines and
proteases at inflammatory foci [i]. They further suggest
that PA inhibitors such as PAl-i play a beneficial physi-
ologic role by restraining the injurious effects of TNF-cx
expression in inflammatory diseases. PAl-i, induced by
endotoxemia, would be appropriately up-regulated to play
this role in the sepsis syndrome [52]. The other venue in
which the interaction between uPA and TNF-a may be
particularly important is in the role of M4s as accessory
cells in immune responses [53-55]. Lymphocyte-derived
products can regulate expression ofM4 uPA and PA in-
hibitors, thereby engaging TNF-a and uPA in mutual feed-
back regulation that would affect subsequent cascades of
intercellular communication [i].
In summary, we have shown that uPA produced endo-
genously by THP-i M4s is necessary for optimal TNF-a
neosynthesis in response to LPS. This regulatory function
of uPA is independent of its function as a plasminogen
activator and requires contributions from the region of its
310 Journal of Leukocyte Biology Volume 59, February 1996
active site, as well as the uPAR-binding domain. This
represents a novel pathway by which the uPA-uPAR sys-
tem, already linked to cellular migration and adhesion,
also exerts feedback regulation on the early phases of M4
activation.
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LETTERS TO THE EDITOR
Within the spectral forms of leprosy ceilbound CD3O
cannot be regarded as an operational marker for the
Th2-like reaction.
Romagnani et al. describe CD3O as a marker for the Th2-type
reaction, where CD3O is preferentially expressed and its sol-
uble form released by human T cell clones producing Th2-
type cytokines [1]. The in vivo relevance is discussed by
showing that high numbers of CD3O+ T cells are found in the
lymph nodes of a patient suffering from Omenn’s syndrome
and the detection of circulating CD3O+ T cells in atopic
patients, both disorders being associated with a Th2-type im-
mune response. The spectral forms of leprosy represent a
model system for the human Thl/Th2 reaction in as much as
Thi reactions predominate in the tuberculoid and Th2 reac-
tions in the leproinatous form of this disease [2]. Thus, we
investigated the application of CD3O as an operational Th2
marker in vivo by performing immunohistological staining on
frozen sections of skin biopsies from patients with leproma-
tous (n i5) and tuberculoid (n 4) leprosy. Hyperplastic
human tonsils and five lymphnode biopsies from patients suf-
fering from Hodgkin’s disease (nodular sclerosis) served as
controls. We evaluated parallel stainings from CD8 (Leu2a,
Becton-Dickinson), CD4 (Leu3a, Becton-Dickinson), CD26
(MIB DS2-7 [3]) and CD3O (Ki-1 [4], Ber-H2 [5]) on these
sections. Staining for CD26 was included as an operational
Thi marker, since high expression of CD26 is found in tuber-
culoid leprosy in contrast to no or very little expression in
lepromatous leprosy. In addition, double immunostaining
demonstrated the coexpression of CD26 and IFNy of T-cells
in tuberculoid leprosy [3]. As expected and described earlier
[4], in frozen tonsil sections positive staining with the anti-
bodies Ki-1 and Ber-H2 was restricted to a few extrafollicular
large cells located at the rim of germinal centers and some-
times within the B-cell follicles. In all Hodgkin cases inves-
tigated, the tumor cells, i.e., Hodgkin and Reed-Sternberg
cells, proved to be positive with the anti CD3O antibodies
used. In contrast, in the leprosy cases a maximum of three to
four CD3O positive T-cells were found per section, and there
was no difference in the accumulation of CD3O positive cells
between the tuberculoid and leprornatous form of leprosy.
From these results we conclude that CD3O does not represent
an operational Th2 marker in this disease model. Because of
the lack of serum we could not elucidate the impact of soluble
CD3O; however, in light of our findings it may be of interest
to investigate this aspect in the different forms of leprosy as
well.
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Culturing unactivated monocytes
In certain situations it is necessary to culture unactivated
monocytes. Therefore, all solutions used to isolate, prepare,
and culture the monocytes must be free of endotoxin or any
other factor that would induce monocyte activation. We found
that certain commercially available leukocyte separation me-
dia (density gradient solutions) appeared to induce cultured
monocytes to express tissue factor (TF) activity even though
they tested negative for endotoxin (as tested by the limulus
lysate test). Therefore, we compared monocyte TF expression
following isolation on three different density gradient media:
